Catalym Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 46

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $150M

  • Investors
  • 15

Catalym General Information

Description

Operator of a biopharmaceutical company intended to transform cancer patients' lives by engaging their own immune systems. The company engages in developing antibodies that transform the tumor micro-environment and substantially improve treatment options by making tumors accessible and susceptible again to the patient's own immune system, enabling cancer patients to improve their survival and quality of life.

Contact Information

Website
www.catalym.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Am Klopferspitz 19
  • Martinsried
  • 82152 Planegg
  • Germany
+49 089
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Am Klopferspitz 19
  • Martinsried
  • 82152 Planegg
  • Germany
+49 089

Catalym Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Catalym Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series D) 16-Jul-2024 $150M Completed Clinical Trials - Phase 2
6. Later Stage VC (Series C) 22-Nov-2022 Completed Clinical Trials - Phase 2
5. Early Stage VC (Series B) 10-Nov-2020 Completed Clinical Trials - Phase 2
4. Early Stage VC Completed Clinical Trials - Phase 2
3. Early Stage VC 01-Jan-2018 Completed Clinical Trials - Phase 2
2. Early Stage VC Completed Startup
1. Seed Round 05-Aug-2016 Completed Startup
To view Catalym’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Catalym Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to transform cancer patients' lives by engaging their own immune system
Drug Discovery
Planegg, Germany
46 As of 2024

Basel, Switzerland
 

Austin, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Catalym Competitors (8)

One of Catalym’s 8 competitors is FoRx Therapeutics, a Venture Capital-Backed company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
FoRx Therapeutics Venture Capital-Backed Basel, Switzerland
Genprex Formerly VC-backed Austin, TX
iOmx Therapeutics Venture Capital-Backed Munich, Germany
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Celldex Therapeutics Formerly VC-backed Hampton, NJ
You’re viewing 5 of 8 competitors. Get the full list »

Catalym Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

Catalym Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023336580-A1 Anti-gdf15 antibody used in a combination treatment of specific patient groups and a dosage regimen for the treatment of cancer Pending 08-Sep-2022
CA-3200687-A1 Anti-gdf15 antibody and a dosage regimen for the treatment of cancer Pending 10-Nov-2020
AU-2021376864-A1 Anti-gdf15 antibody and a dosage regimen for the treatment of cancer Pending 10-Nov-2020
EP-4243928-A1 Anti-gdf15 antibody and a dosage regimen for the treatment of cancer Pending 10-Nov-2020
US-20240043517-A1 Anti-gdf15 antibody and a dosage regimen for the treatment of cancer Pending 10-Nov-2020 C07K16/22
To view Catalym’s complete patent history, request access »

Catalym Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Catalym Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bioqube Ventures Venture Capital Minority
Brandon Biocatalyst Venture Capital Minority
Canaan Partners Venture Capital Minority
Gilde Healthcare Venture Capital Minority
Omega Funds Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial

Catalym FAQs

  • When was Catalym founded?

    Catalym was founded in 2016.

  • Where is Catalym headquartered?

    Catalym is headquartered in Planegg, Germany.

  • What is the size of Catalym?

    Catalym has 46 total employees.

  • What industry is Catalym in?

    Catalym’s primary industry is Drug Discovery.

  • Is Catalym a private or public company?

    Catalym is a Private company.

  • What is Catalym’s current revenue?

    The current revenue for Catalym is .

  • How much funding has Catalym raised over time?

    Catalym has raised $271M.

  • Who are Catalym’s investors?

    Bioqube Ventures, Brandon Biocatalyst, Canaan Partners, Gilde Healthcare, and Omega Funds are 5 of 15 investors who have invested in Catalym.

  • Who are Catalym’s competitors?

    FoRx Therapeutics, Genprex, iOmx Therapeutics, Inovio Pharmaceuticals, and Celldex Therapeutics are some of the 8 competitors of Catalym.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »